Search

Much has been written about instructor attitudes towards lecture capture, particularly concerning political issues such as opt-out policies and the use of recordings by management. Additionally, the pedagogical concerns of lecturers have been extensively described and focus on the belief that recording lectures will impact on attendance and will reduce interactivity and active learning activities in lectures. However, little work has looked at the relationship between attitudes towards lecture capture and broader conceptions of learning and teaching. In this pre-registered study, we administered the Conceptions of Learning and Teaching scale and a novel lecture capture attitude scale to 159 higher education teachers. We found that appreciation of active learning predicted more positive attitudes towards lecture recordings as an educational support tool, whilst higher teacher-centred scores predicted greater concern about the negative educational impact of recordings. The effects observed were small; however, they are strong evidence against the view that it is instructors who value participatory and active learning that are opposed to lecture capture. Exploratory analyses also suggested that those who did not view recordings as an essential educational resource record fewer of their lectures, highlighting the real-world impact that attitudes can have, and further strengthening the need for staff to be provided with evidence-based guidance upon which to base their teaching practice. Data, analysis code, and the pre-registration are available athttps://osf.io/uzs3t/.

One of the most critical drivers of innovation in the drug delivery field is commercialization potential, which is facilitated by intellectual property (IP) protection primarily in the form of patents. This chapter provides a detailed overview of the evolution of the global IP landscape around drug delivery over the past 30 years, paying particular attention to the three most widely used drug delivery systems: oral, topical, and parenteral. Emerging areas of IP growth including targeted, nanoscale, and immunoconjugate drug delivery systems are highlighted, as is the importance and core requirements of a program to proactively monitor the dynamic IP landscape.